Navigation Links
Still River Systems Announces Operation of the World's Highest Magnetic Field Cyclotron

LITTLETON, Mass., May 21 /PRNewswire/ -- Still River Systems announces the successful development and operation of the world's highest magnetic field cyclotron as part of the development of its Monarch250(TM) proton therapy system. This cyclotron is operating at 10 Tesla and conclusively demonstrates that cyclotrons at this high field strength can be designed and optimized for proton radiation therapy. By increasing the operating magnetic field, Still River Systems is developing a cyclotron that weighs less than 20 tons, a 90% reduction over the current generation of proton therapy cyclotrons. "We are excited to report this technical breakthrough," says Kenneth Gall, Ph.D., Chief Technology Officer and Founder of Still River Systems. "While magnets of this strength are already in use in medical applications, the challenge has been to operate a cyclotron at this very large magnetic field."

Conventional proton radiation therapy cyclotrons are based on non-superconducting technology, and operate at low magnetic fields. In 2004, Still River Systems partnered with the Massachusetts Institute of Technology (MIT) to develop this next generation of proton therapy cyclotron using high magnetic field technology currently used in research and Magnetic Resonance Imaging (MRI) applications. "Our goal is to make proton radiation therapy treatment available to hospitals and cancer centers worldwide. This was only possible through a significant reduction in the cost and size of the proton therapy equipment and facility which can be achieved by using high-magnetic field technology," says Marc Buntaine, Chief Executive Officer of Still River Systems.

About The Monarch250

The Monarch250 is the next generation of proton radiation therapy systems. Based on Still River Systems high-magnetic field cyclotron, combined with proven proton therapy technology, the Monarch250 is being integrated with well established clinical systems such as patient radiographic and cone beam CT imaging, high-precision robotic treatment couch, oncology information systems and treatment planning systems. The compact, precise and affordable design of the Monarch250 proton therapy system provides the most versatile proton treatment capabilities, enhancing existing department capacity. For large multiple room proton centers, the Monarch250 unique configuration of one-cyclotron for each room will provide the most reliable, efficient and economical approach to proton therapy. The Monarch250 has not been cleared for commercial distribution/clinical use by the US Food and Drug Administration and is currently in development.

About Still River Systems

Still River Systems, based in Littleton, Massachusetts, is dedicated to providing physicians and their patients access to high quality, cost-effective proton therapy solutions, and to help establish this superior treatment modality as a standard of care for patients worldwide. Still River Systems is developing the Monarch250, an affordable, precise and compact proton therapy system for cancer treatment. For more information on Still River Systems and the Monarch250 Proton Therapy System, please call 978-540-1500 or visit their website @

SOURCE Still River Systems
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
2. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
3. Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated
4. Federal nanotech risk research plan still comes up short
5. RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
6. Dr. Arie S. Belldegrun, MD, FACS Joins Two River Group Holdings as Chairman and Partner
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
9. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. NxStage Medical Provides Update on Medisystems Acquisition
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
Breaking Biology News(10 mins):